Scribe Therapeutics Q2 FY26 net loss narrows 34.34% to $6.5 million; revenue falls 61.22% to $1.9 million
SCTX•Pipeline update
The company initiated a Phase 1 trial of LDL-C therapy STX-1150. Management said the period was "transformational," with funding expected into H1 2029.
Quarterly results
Scribe Therapeutics posted a Q2 net loss of USD 6.5 million, narrowing from USD 9.9 million a year earlier.
Collaboration revenue fell 61.22% to USD 1.9 million on lower reimbursable R&D activity and reduced revenue recognition.
Expenses and cash position
R&D expense dropped 36.69% to USD 8.8 million on lower personnel and preclinical spending, partly offset by STX-1150 trial work.
Cash, cash equivalents, and marketable securities were USD 43 million at June 30, 2026; net IPO and Sanofi placement proceeds were about USD 140.6 million.
